Precision BioSciences
A gene editing company specializing in in vivo gene editing with its ARCUS platform.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $300k | Private Placement VC |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 68 % | 104 % | 9 % | 376 % | (78 %) | 94 % | 41 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (401 %) | (393 %) | (408 %) | (25 %) | (392 %) | (67 %) | (23 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (423 %) | (418 %) | (449 %) | (26 %) | (445 %) | (126 %) | 10 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 415 % | 371 % | 404 % | 100 % | 334 % | 110 % | 87 % |
Source: Company filings or news article
Related Content
Precision BioSciences is a biotechnology company specializing in genome editing to address critical health and food challenges. Utilizing its proprietary ARCUS Genome Editing technology, the company aims to eliminate cancers, cure genetic diseases, and develop safer, more productive food sources. Precision BioSciences operates in the healthcare and agriculture markets, serving patients, medical institutions, and agricultural producers. The company's business model revolves around research and development, clinical trials, and partnerships with healthcare and agricultural organizations. Revenue is generated through licensing agreements, partnerships, and product sales.
Keywords: Genome Editing, Cancer Immunotherapy, Gene Therapy, ARCUS Technology, Biotechnology, Healthcare, Agriculture, Genetic Diseases, Food Safety, Clinical Trials.